Mailed At-Home HPV Kits Sharply Raised Screening Among Overdue Patients

CATEGORY: DISEASE PREVENTION

Mailing an at-home HPV self-collection kit to patients overdue for cervical cancer screening more than doubled the share who actually got screened—41.1% within six months, versus 17.4% with reminder phone calls alone—in a randomized trial of 2,474 patients published in JAMA Internal Medicine.¹ Adding a follow-up call from a patient navigator nudged participation slightly higher still, to 46.6%.

A Cancer Screen That Fits in an Envelope

Nearly all cervical cancers are caused by long-lasting infection with HPV, the human papillomavirus, and modern screening rests on finding the high-risk types of that virus early. The HPV test is what makes home participation possible: unlike the traditional Pap smear, which requires a clinician to collect cells from the cervix during a pelvic exam, an HPV test can run on a sample a woman collects herself with a simple vaginal swab. The kit travels by mail in both directions: it arrives at home, the sample goes back to the laboratory, and the result enters the patient’s record like any other screening test.

Three Groups Drawn From the Patients Screening Usually Misses

The PRESTIS trial ran inside a publicly funded safety-net health system in Houston, enrolling a random sample of patients who were behind on cervical cancer screening—including some with no screening on record at all. Their median age was 49; 94% belonged to racial or ethnic minority groups, and more than half were covered by the county’s financial assistance program. Every participant got a reminder phone call inviting them to clinic-based screening. Two of the three randomly assigned groups were also mailed a self-collection kit, and one of those additionally received a telephone call from a patient navigator—a staff member whose job is to help patients over practical hurdles like transportation, scheduling, and paperwork. The outcome was concrete and checkable: attendance for clinic screening, or a returned kit, within six months, verified through health records.

Out of Every Hundred Phone Calls, Seventeen Screens—Until the Kit Arrived

Picture a hundred of these patients receiving only the reminder call: about seventeen ended up screened within six months. In the hundred who also found a kit in the mailbox, about forty-one did—2.36 times as many, with the trial’s precision leaving little doubt (95% confidence interval, 1.99 to 2.80). The navigator call on top of the kit lifted the number to about forty-seven per hundred, a gain the researchers themselves characterize as modest compared with the jump produced by the kit itself. In absolute terms, mailing the kit meant roughly 24 additional people screened for every 100 reached.

The Same Idea Worked in Appalachia

The Houston result does not stand alone. A separate randomized trial mailed HPV self-collection kits to underscreened women aged 30 to 64 across the Appalachian regions of Kentucky, Ohio, Virginia, and West Virginia, and found 14.9% got screened versus 5.0% of those sent a conventional reminder letter—the same pattern at lower overall participation.² One caution belongs alongside both results: returning a kit is a first step, not a finish line. A positive HPV result is not a cancer diagnosis—most HPV infections never become cancer—and screening prevents disease only when abnormal results are followed by further evaluation, which is exactly the stage where patient navigators may matter most.

Key Takeaways

• In a 2,474-person randomized trial in a Houston safety-net system, mailed HPV self-collection kits raised six-month screening participation to 41.1%, versus 17.4% with reminder phone calls alone—about 24 more people screened per 100 reached.
• Adding a patient navigator call brought participation to 46.6%, a modest further gain compared with the effect of the kit itself.
• A separate randomized trial in Appalachia found the same pattern (14.9% versus 5.0%), so the finding does not rest on one health system.
• A returned kit is a screening step, not a diagnosis: most HPV infections never lead to cancer, and the benefit of screening depends on follow-up of abnormal results.

References

1. Montealegre JR, Hilsenbeck SG, Bulsara S, et al. Self-Collection for Cervical Cancer Screening in a Safety-Net Setting: The PRESTIS Randomized Clinical Trial. JAMA Internal Medicine. 2025;185(9):1119–1127. link
2. Reiter PL, Shoben AB, Cooper S, et al. A Mail-Based HPV Self-Collection Program to Increase Cervical Cancer Screening in Appalachia: Results of a Group Randomized Trial. Cancer Epidemiology, Biomarkers & Prevention. 2025;34(1):159–165. link